SIRT2-IN-9 (compound 12) is a selective inhibitor of SRIT2 with an IC50 value of 1.3 μM. SIRT2-IN-9 inhibits proliferative activity of MCF-7 breast cancer cells. SIRT2-IN-9 can be used for the research of cancer[1].
SIRT2-IN-9 (1-100 μM; 15 min) dose-dependently inhibits SRIT2 with an IC50 value of 1.3 μM, and inhibits SRIT1 and SRIT3 with IC50s ＞300 μM[1].
SIRT2-IN-9 (0-50 μM; 72 h) affects cell viability of MCF-7 cells[1].
SIRT2-IN-9 (0-50 μM; 6 h) affects acetylation of α-tubulin protein[1].
Cell Proliferation Assay[1]
| Cell Line: | MCF-7 breast cancer cell line |
| Concentration: | 0-50 μM |
| Incubation Time: | 72 hours |
| Result: | Dose-dependently inhibited cell proliferation of MCF-7 breast cancer cells. |
Western Blot Analysis[1]
| Cell Line: | MCF-7 breast cancer cell line |
| Concentration: | 6.25, 12.5, 25 and 50 μM |
| Incubation Time: | 6 hours |
| Result: | Dose-dependently increased acetylation of α-tubulin protein. |